Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Current Deferred Revenue: 2015-2025

Historic Current Deferred Revenue for Editas Medicine (EDIT) over the last 9 years, with Sep 2025 value amounting to $54.2 million.

  • Editas Medicine's Current Deferred Revenue fell 21.32% to $54.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.2 million, marking a year-over-year decrease of 21.32%. This contributed to the annual value of $60.4 million for FY2024, which is 12.29% down from last year.
  • Latest data reveals that Editas Medicine reported Current Deferred Revenue of $54.2 million as of Q3 2025, which was down 0.00% from $54.2 million recorded in Q2 2025.
  • Editas Medicine's 5-year Current Deferred Revenue high stood at $89.4 million for Q1 2021, and its period low was $54.2 million during Q2 2025.
  • Over the past 3 years, Editas Medicine's median Current Deferred Revenue value was $68.9 million (recorded in 2024), while the average stood at $64.3 million.
  • In the last 5 years, Editas Medicine's Current Deferred Revenue slumped by 51.01% in 2021 and then rose by 3.27% in 2023.
  • Over the past 5 years, Editas Medicine's Current Deferred Revenue (Quarterly) stood at $72.2 million in 2021, then declined by 4.62% to $68.9 million in 2022, then remained steady at $68.9 million in 2023, then fell by 12.29% to $60.4 million in 2024, then dropped by 21.32% to $54.2 million in 2025.
  • Its Current Deferred Revenue was $54.2 million in Q3 2025, compared to $54.2 million in Q2 2025 and $56.2 million in Q1 2025.